FibroGen names new vice president of clinical development

Dr Yu was most recently vice president of clinical research at Anesiva. Prior to Anesiva, Dr Yu was director of clinical development, at Alza, a subsidiary of Johnson & Johnson.

Dr Yu has received a BS in chemical engineering and an MD both from the University of California, Davis, followed by residency training at Stanford Medical School.

Frank Valone, chief medical officer of FibroGen, said: “Peony’s experience in leading multifunctional clinical teams with proven success in advancing investigational products through all stages of clinical development through regulatory approval will be an important asset to FibroGen. We look forward to her leadership of our multiple clinical programs in the US and globally.”